A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease
Pacifico L, Bonci E, Di Martino M, Versacci P, Andreoli G, Silvestri LM, Chiesa C
Nutrition, metabolism, and cardiovascular diseases : NMCD · 84 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Sapienza Università di Roma
- Universidad u hospital
- Sapienza University of Rome
Según 2 financiadores declarados.
Publicación
- Publicado
- 2015-04-24 · Nutr Metab Cardiovasc Dis · vol. 25 · número 8 · págs. 734–741
- Editorial
- Elsevier BV
- Citado
- 103 citas · más que el 98% de estudios similares · 9.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 36 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Liver Disease Diagnosis and Treatment · Diet, Metabolism, and Disease
- Palabras clave
- docosahexaenoic acid, omega-3 supplementation, non-alcoholic fatty liver disease, liver fat, children, overweight, visceral adipose tissue, epicardial adipose tissue, cardiovascular risk factors, insulin sensitivity, triglycerides, left ventricular function, alanine aminotransferase
- MeSH
- liver, pericardium, adipose tissue, humans, insulin, alanine transaminase, docosahexaenoic acids, fatty acids, unsaturated, triglycerides, magnetic resonance imaging, biopsy, body mass index, treatment outcome, fasting, risk factors, double-blind method, ventricular function, left, adolescent, child, female, male, intra-abdominal fat, overweight, non-alcoholic fatty liver disease
7 autores
- Lucia Pacifico🇮🇹Sapienza University of Rome
- Enea Bonci🇮🇹Sapienza University of Rome
- Michele Di Martino🇮🇹Sapienza University of Rome
- Paolo Versacci🇮🇹Sapienza University of Rome
- Giada Andreoli🇮🇹Sapienza University of Rome
- Lucia Martina Silvestri🇮🇹Sapienza University of Rome
- Claudio Chiesa🇮🇹 · autor de correspondenciaIstituto di Farmacologia Traslazionale; National Research Council
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
Very little information is available on whether docosahexaenoic acid (DHA) supplementation has a beneficial effect on liver fat and cardiovascular disease (CVD) risk factors in children with nonalcoholic fatty liver disease (NAFLD). In a double-blind, placebo-controlled randomized trial we investigated whether 6-month treatment with DHA improves hepatic fat and other fat depots, and their associated CVD risk factors in children with biopsy-proven NAFLD.
Methods and results
Of 58 randomized children, 51 (25 DHA, 26 placebo) completed the study. The main outcome was the change in hepatic fat fraction as estimated by magnetic resonance imaging. Secondary outcomes were changes in visceral adipose tissue (VAT), epicardial adipose tissue (EAT), and left ventricular (LV) function, as well as alanine aminotransferase (ALT), triglycerides, body mass index-standard deviation score (BMI-SDS), and insulin sensitivity. At 6 months, the liver fat was reduced by 53.4% (95% CI, 33.4-73.4) in the DHA group, as compared with 22.6% (6.2-39.0) in the placebo group (P = 0.040 for the comparison between the two groups). Likewise, in the DHA group VAT and EAT were reduced by 7.8% (0-18.3) and 14.2% (0-28.2%), as compared with 2.2% (0-8.1) and 1.7% (0-6.8%) in the placebo group, respectively (P = 0.01 for both comparisons). There were no significant between-group changes for LV function as well as BMI-SDS and ALT, while fasting insulin and triglycerides significantly decreased in the DHA-treated children (P = 0.028 and P = 0.041, respectively).
Conclusions
DHA supplementation decreases liver and visceral fat, and ameliorates metabolic abnormalities in children with NAFLD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.